Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia.
Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments. Because its use in stroke is not as established as other indications, ITB therapy has not been subjected to rigorous investigation. There is limited evidence to guide clinicians regarding application of this therapy in this patient population. This article aims to review the available scientific literature and the opinion of several experts on the topic. It will also describe the recommendations of these experts with regard to addressing common clinical situations that may influence treatment decisions in the stroke population.
Francisco
Gerard E
GE
Physical Medicine and Rehabilitation, Brain Injury and Stroke Program, University of Texas Health Science Center-Houston, The Institute for Rehabilitation and Research, Houston, Texas, USA.
Yablon
Stuart A
SA
Schiess
Mya C
MC
Wiggs
Laura
L
Cavalier
Steven
S
Grissom
Samuel
S
D001418:Baclofen / Q000008:administration & dosage*; D006801:Humans; D007278:Injections, Spinal; D009125:Muscle Relaxants, Central / Q000008:administration & dosage*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000150:complications*
D009125:Muscle Relaxants, Central; D001418:Baclofen